Overview
NICE is unable to make a recommendation on isatuximab (Sarclisa) with carfilzomib (Kyprolis) and dexamethasone for treating relapsed or refractory multiple myeloma because Sanofi did not provide an evidence submission.
Last reviewed: 22 September 2021
Next review: We will review this decision if the company decides to make a submission.